2026 Q3 - tulosraportti
UUTTA
1 päivä sitten
‧1 t 2 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 1 | ||
| 6 | ||
| 3 | ||
| 3 | ||
| 1 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 17.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 5.11. | ||
2026 Q2 - tulosraportti 6.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 17.2. | ||
2025 Q3 - tulosraportti 6.11.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·3 t sittenHad to get back to the keys today, brief remark. Rarely do I praise "Oracle Hansen" from Nordnet but his email with "good advice" deserves to be listed for everyone's knowledge and info - this written in the wake of the US midterm elections. What should you as an investor do? Make sure your investments match your risk profile and investment horizon. Maintain calm and perspective. Remember to spread your risk and invest slowly. All crises blow over, even if it looks difficult. It may sound superfluous, but we all learn from crises.
SorteSvane Når du i går, skrev om din forventede positive kursreaktion i dag, dagen efter Q3, hvordan passer det ind i billedet med "at bavare roen og overblikket"? Du skriver om det store potentiale i aktien, mens du også skriver du ikke er langsigtet. Hvordan hænger det sammen? Hilsen personen der gerne vil blive klogere på andre aktører- ·3 t sittenI think it stabilizes and acquisitions happen over the day, "someone" just needs to skim the cream off - so my guess is, also based on an otherwise decent Q3 presentation yesterday, that no one should jump ship, but people decide that for themselves of course. Good cold weekend from here
Agreed. Be careful not to panic sell. If tech stocks in the US fall further, the money will most likely go into the healthcare sector, among others. When the panic has settled things will stabilize, that is at least my assessment. - ·3 t sitten"wise-guys" who analyzed the whole presentation yesterday ! Where is the pain threshold today (share price) and does anyone have a guess where we will land in 8 hours. Price drop was expected - regardless of "how good" Q3 was yesterday@Progression you sayen funny man (think you a man, it's probably 80/20) men women this forum. With all your scientific studies about stock prices in mind, you should know (latest NOVO) that just a tiny pip of good news, the price SHOOTS up, and then when people catch their breath a little - it often loses steam. I deleted a post at 8:59 shortly after where I predicted the price drop today, - that was AFTER I had seen the presentation yesterday (which you apparently also base your views on) I am not long-term in GENMAB, it's about a quick gain but that doesn't mean people should rush into the boats today. It stabilizes, no matter what your analyses conjure up Good day and win for time PROGRESS
- ·5 t sittenSøren Løntoft Hansen writes about "opex" (operating expenses) for 2027 and market expectations. Genmab's CFO confirmed yesterday that he considered Bloomberg's consensus to be in accordance with Genmab's expectation, even though Genmab will not have their annual guidance for 2027 ready until February. It thus looks like R&D hits approx. 2.3 billion USD in 2027 from 1.6 billion USD in 2025. Impressive increase of almost 50 % over 2 years. Winkel, who is "researcher at heart", must feel like being in heaven with all those resources, and one must also remember that Genmab does not develop if Genmab does not invest. Genmab is good at that, but on a rare occasion one might wish that Winkel talked a bit more about current shareholder value as well as the long-term value. Well, we might get closer to that point, if it even exists, if all 3 candidates end up as the great successes that Genmab is working for. The road is still long and bumpy, but it has become significantly safer after October 2026 and triple data from phase 3. The potential can, if things go very well, be far greater than share price 3000-4000. Regards, the long-term, persistent and critical Genmab writer - and no, this post is written 100 % by me, without the slightest assistance from AI.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 68 124 | 68 124 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 68 124 | 68 124 | 0 | 0 |
2026 Q3 - tulosraportti
UUTTA
1 päivä sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·3 t sittenHad to get back to the keys today, brief remark. Rarely do I praise "Oracle Hansen" from Nordnet but his email with "good advice" deserves to be listed for everyone's knowledge and info - this written in the wake of the US midterm elections. What should you as an investor do? Make sure your investments match your risk profile and investment horizon. Maintain calm and perspective. Remember to spread your risk and invest slowly. All crises blow over, even if it looks difficult. It may sound superfluous, but we all learn from crises.SorteSvane Når du i går, skrev om din forventede positive kursreaktion i dag, dagen efter Q3, hvordan passer det ind i billedet med "at bavare roen og overblikket"? Du skriver om det store potentiale i aktien, mens du også skriver du ikke er langsigtet. Hvordan hænger det sammen? Hilsen personen der gerne vil blive klogere på andre aktører
- ·3 t sittenI think it stabilizes and acquisitions happen over the day, "someone" just needs to skim the cream off - so my guess is, also based on an otherwise decent Q3 presentation yesterday, that no one should jump ship, but people decide that for themselves of course. Good cold weekend from hereAgreed. Be careful not to panic sell. If tech stocks in the US fall further, the money will most likely go into the healthcare sector, among others. When the panic has settled things will stabilize, that is at least my assessment.
- ·3 t sitten"wise-guys" who analyzed the whole presentation yesterday ! Where is the pain threshold today (share price) and does anyone have a guess where we will land in 8 hours. Price drop was expected - regardless of "how good" Q3 was yesterday@Progression you sayen funny man (think you a man, it's probably 80/20) men women this forum. With all your scientific studies about stock prices in mind, you should know (latest NOVO) that just a tiny pip of good news, the price SHOOTS up, and then when people catch their breath a little - it often loses steam. I deleted a post at 8:59 shortly after where I predicted the price drop today, - that was AFTER I had seen the presentation yesterday (which you apparently also base your views on) I am not long-term in GENMAB, it's about a quick gain but that doesn't mean people should rush into the boats today. It stabilizes, no matter what your analyses conjure up Good day and win for time PROGRESS
- ·5 t sittenSøren Løntoft Hansen writes about "opex" (operating expenses) for 2027 and market expectations. Genmab's CFO confirmed yesterday that he considered Bloomberg's consensus to be in accordance with Genmab's expectation, even though Genmab will not have their annual guidance for 2027 ready until February. It thus looks like R&D hits approx. 2.3 billion USD in 2027 from 1.6 billion USD in 2025. Impressive increase of almost 50 % over 2 years. Winkel, who is "researcher at heart", must feel like being in heaven with all those resources, and one must also remember that Genmab does not develop if Genmab does not invest. Genmab is good at that, but on a rare occasion one might wish that Winkel talked a bit more about current shareholder value as well as the long-term value. Well, we might get closer to that point, if it even exists, if all 3 candidates end up as the great successes that Genmab is working for. The road is still long and bumpy, but it has become significantly safer after October 2026 and triple data from phase 3. The potential can, if things go very well, be far greater than share price 3000-4000. Regards, the long-term, persistent and critical Genmab writer - and no, this post is written 100 % by me, without the slightest assistance from AI.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 1 | ||
| 6 | ||
| 3 | ||
| 3 | ||
| 1 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 17.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 5.11. | ||
2026 Q2 - tulosraportti 6.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 17.2. | ||
2025 Q3 - tulosraportti 6.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 68 124 | 68 124 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 68 124 | 68 124 | 0 | 0 |
2026 Q3 - tulosraportti
UUTTA
1 päivä sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 17.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 5.11. | ||
2026 Q2 - tulosraportti 6.8. | ||
2026 Q1 - tulosraportti 7.5. | ||
2025 Q4 - tulosraportti 17.2. | ||
2025 Q3 - tulosraportti 6.11.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·3 t sittenHad to get back to the keys today, brief remark. Rarely do I praise "Oracle Hansen" from Nordnet but his email with "good advice" deserves to be listed for everyone's knowledge and info - this written in the wake of the US midterm elections. What should you as an investor do? Make sure your investments match your risk profile and investment horizon. Maintain calm and perspective. Remember to spread your risk and invest slowly. All crises blow over, even if it looks difficult. It may sound superfluous, but we all learn from crises.SorteSvane Når du i går, skrev om din forventede positive kursreaktion i dag, dagen efter Q3, hvordan passer det ind i billedet med "at bavare roen og overblikket"? Du skriver om det store potentiale i aktien, mens du også skriver du ikke er langsigtet. Hvordan hænger det sammen? Hilsen personen der gerne vil blive klogere på andre aktører
- ·3 t sittenI think it stabilizes and acquisitions happen over the day, "someone" just needs to skim the cream off - so my guess is, also based on an otherwise decent Q3 presentation yesterday, that no one should jump ship, but people decide that for themselves of course. Good cold weekend from hereAgreed. Be careful not to panic sell. If tech stocks in the US fall further, the money will most likely go into the healthcare sector, among others. When the panic has settled things will stabilize, that is at least my assessment.
- ·3 t sitten"wise-guys" who analyzed the whole presentation yesterday ! Where is the pain threshold today (share price) and does anyone have a guess where we will land in 8 hours. Price drop was expected - regardless of "how good" Q3 was yesterday@Progression you sayen funny man (think you a man, it's probably 80/20) men women this forum. With all your scientific studies about stock prices in mind, you should know (latest NOVO) that just a tiny pip of good news, the price SHOOTS up, and then when people catch their breath a little - it often loses steam. I deleted a post at 8:59 shortly after where I predicted the price drop today, - that was AFTER I had seen the presentation yesterday (which you apparently also base your views on) I am not long-term in GENMAB, it's about a quick gain but that doesn't mean people should rush into the boats today. It stabilizes, no matter what your analyses conjure up Good day and win for time PROGRESS
- ·5 t sittenSøren Løntoft Hansen writes about "opex" (operating expenses) for 2027 and market expectations. Genmab's CFO confirmed yesterday that he considered Bloomberg's consensus to be in accordance with Genmab's expectation, even though Genmab will not have their annual guidance for 2027 ready until February. It thus looks like R&D hits approx. 2.3 billion USD in 2027 from 1.6 billion USD in 2025. Impressive increase of almost 50 % over 2 years. Winkel, who is "researcher at heart", must feel like being in heaven with all those resources, and one must also remember that Genmab does not develop if Genmab does not invest. Genmab is good at that, but on a rare occasion one might wish that Winkel talked a bit more about current shareholder value as well as the long-term value. Well, we might get closer to that point, if it even exists, if all 3 candidates end up as the great successes that Genmab is working for. The road is still long and bumpy, but it has become significantly safer after October 2026 and triple data from phase 3. The potential can, if things go very well, be far greater than share price 3000-4000. Regards, the long-term, persistent and critical Genmab writer - and no, this post is written 100 % by me, without the slightest assistance from AI.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 1 | ||
| 6 | ||
| 3 | ||
| 3 | ||
| 1 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 68 124 | 68 124 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 68 124 | 68 124 | 0 | 0 |